Developing lawLegislationStandards

BICO Endorses FDA Modernization Act of 2021

To promote the use bioprinting and end animal testing for drugs and cosmetics

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

BICO, a leading bio convergence company, announced today it is endorsing the bipartisan FDA Modernization Act of 2021. The bill, H.R. 2565 / S.2952, would allow drug and cosmetic makers to develop new products using non-animal models including cell-based assays, organ chips and micro physiological systems, sophisticated computer modeling, and other human biology-based test methods. Since its founding, BICO has been a leader in the effort to end animal testing in the life sciences community, and plan to actively build support for the legislation.

Each year more than 100 million animals are estimated to be experimented on and euthanized for use in biomedical research in the United States alone, according to the Humane Society. This is in large part due to the 1938 Federal Food, Drug, and Cosmetic Act which requires that all new products be tested on animals to ensure safety and efficacy, regardless of if it provides scientific value. More than 80 years later, technological breakthroughs including tissue engineering, single-cell isolation, live-cell imaging and others can be converged to accelerate drug development without the use of animal experimentation.

BICO Endorses FDA Modernization Act of 2021 to promote the use bioprinting technologies and end animal testing Human tissue replacement models are undoubtedly a better indicator of toxicity and efficacy than dogs or mice, which share very little physiology to humans,” commented Alex Armento, President of MatTek, a BICO group company. “By giving researchers the choice of testing on animals or human models, we’ll ultimately enable them to make the best decision based on the science.”

There is an ongoing global debate concerning the relevance of animal testing. In September 2021, the European Parliament adopted a resolution calling on the European Commission to establish an action plan to actively phase out animal experiments. This year, Mexico also banned the use of animal testing for cosmetic development while also banning imports of products tested on animals worldwide meaning U.S. developed products forced to test on animals will lose market access.

“There is no bigger ethical issue plaguing the life sciences industry in the United States today than this mandate on animal experimentation,” says Erik Gatenholm, CEO and co-founder of BICO. “Passing this law is not only the right thing to do, but also will advance Health 4.0 and ensure the U.S. continues to be a global life science leader in the coming decades.”

Nearly all BICO’s 13 group companies contribute to advancing drug development including several that provide direct alternatives to animal testing, including:

  • CELLINK – 3D bioprinting to fabricate human tissue samples that provide much more physiologically relevant drug testing than animals.
  • MatTek – In vitro human tissue models including skin, ocular, oral, respiratory, and intestinal tissue models to replicate toxicity and efficacy of human cells.
  • Visikol – In Vitro assays for drug screening and toxicity assessment using high content screening, confocal microscopy, ELISA, and other assays.
  • SCIENION – automated precision dispensing that can be used to accurately and reproducible distribute physiologically relevant biological material.
  • Cellenion – single large-particle sorting and dispensing technology that enables the handling of complex 3D cellular models such as spheroids and organoids, and that can replace animal testing in pre-clinical research.“

Reference documents:
United States House Bill, H.R 2565 – FDA Modernization Act of 2021
United States Senate Bill, S.2952 – FDA Modernization Act of 2021
Article in the Cambridge Quarterly of Healthcare Ethics “The Flaws and Human Harms of Animal Experimentation”

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he co-founded London-based 3dpbm. Today the company publishes the leading news and insights websites 3D Printing Media Network and Replicatore, as well as 3D Printing Business Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!